Answer
Feb 03, 2026 - 08:03 AM
Larotrectinib is a targeted cancer therapy that works by inhibiting TRK (tropomyosin receptor kinase) proteins produced by NTRK gene fusions in cancer cells. By blocking these proteins, larotrectinib stops the growth and spread of tumors driven by NTRK gene fusions.
